inhibrx.com
Get leads like Inhibrx — and thousands more
Build targeted lists by tech stack, traffic, and more
Inhibrx: The Biotech Bet on Single-Domain Antibodies
A deep dive into a clinical-stage company using protein engineering to reshape oncology and immunology.
In the high-stakes world of biotech, Inhibrx isn't chasing trends; they are building the architecture of the future. Anchored by proprietary single-domain antibody technology, they are quietly engineering a pipeline designed to tackle some of medicine's most stubborn challenges.
"They aren't just discovering drugs; they are engineering the delivery mechanisms from the ground up."
The Science Behind the Hype
Inhibrx’s competitive edge lies in its mastery of protein engineering. By leveraging a single-domain antibody platform, they create molecules that are smaller, more stable, and potentially more penetrative than traditional antibodies. This isn't incremental improvement; it's a fundamental rethinking of how biologics bind to targets, offering a distinct advantage in oncology and rare diseases.
Financial Velocity & Valuation
With nearly $20M in revenue and a massive $469M war chest, Inhibrx is positioned for aggressive clinical expansion. While 178 employees might seem lean for a biotech of this valuation, it suggests a highly focused R&D engine rather than a bloated corporate structure. Their financials signal a company in the critical transition phase from pure research to commercial readiness.
The traffic data reveals a company with a highly specialized audience. With 44% direct traffic and 33% organic search, their web presence is driven by stakeholders actively seeking them out—investors, partners, and patients—rather than casual browsing. The search volume for terms like 'INBX stock news' and 'inhibrx dr5' confirms they are on the radar of the financial and scientific communities.
- Proprietary single-domain antibody platform offers unique IP protection.
- Strong cash runway relative to headcount suggests efficient capital allocation.
- Focused leadership under Mark Lappe driving commercial strategy.
- Pipeline targets high-value areas in oncology and immunology.
The Verdict: A High-Potential Specialist
Inhibrx is a classic 'buy' signal for those who understand biotech valuation, but a ghost in the machine for the casual observer.
What tech stack does Inhibrx use?
How much traffic does Inhibrx get?
Traffic & Engagement
Traffic Sources
Where is Inhibrx's audience located?
What keywords does Inhibrx rank for?
5 keywordsHow is Inhibrx's SEO?
Meta Tags
Inhibrx | Discover our clinical-stage biotechnology company.
Anchored by our protein-engineering expertise and our proprietary single-domain antibody platform, we’ve developed a unique pipeline of therapeutic candidates.
H1 Tags
Schema Types
What is Inhibrx's revenue?
Who works at Inhibrx?
Loading leads...
What do customers think of Inhibrx?
No Trustpilot reviews available for this company.
Frequently Asked Questions about Inhibrx
What is Inhibrx's Revenue?
What does Inhibrx do?
How fast is Inhibrx growing?
What technologies does Inhibrx use?
Who are Inhibrx's competitors?
Export Data
Unlock all exports
Download CSVs, JSONs & full reports
How to contact Inhibrx?
Contact Information
Export inhibrx.com Data
Download the complete tech stack, analytics, leads, and company data for inhibrx.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.
Raw JSON Data
Click "Show" to view the raw API response data
About inhibrx.com
Anchored by our protein-engineering expertise and our proprietary single-domain antibody platform, we’ve developed a unique pipeline of therapeutic candidates.
Company Overview
inhibrx.com Social Media
Contact inhibrx.com
Phone Numbers
Technology Stack
inhibrx.com uses 25 technologies across their website including AccessiBe, Vimeo, Font Awesome, and more.
Accessibility
AccessiBe
Video
Vimeo
Fonts
Font Awesome
Backend Frameworks
Laravel
Programming Languages
PHP
CMS
Squarespace, Webflow, WordPress
Traffic & Audience
inhibrx.com receives approximately 5.4K monthly visitors and ranks #3,757,362 globally. The website has a bounce rate of 56% with visitors viewing an average of 1.5 pages per visit. Users spend an average of 0:14 on the site.
The majority of inhibrx.com's traffic comes from undefined, .
Frequently Asked Questions
What is inhibrx.com?
What technologies does inhibrx.com use?
How do I contact inhibrx.com?
What are inhibrx.com's social media accounts?
Is inhibrx.com hiring?
How popular is inhibrx.com?
Related Searches
This page provides publicly available information about inhibrx.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit inhibrx.com directly at https://inhibrx.com.